# OnCo record decitabine-cedazuridine (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/decitabine-cedazuridine/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "decitabine-cedazuridine" ;
  schema:name "Decitabine + cedazuridine (oral)"@en ;
  schema:alternateName "Decitabine-cedazuridine"@en, "Oral decitabine"@en, "Cedazuridine"@en, "Inqovi" ;
  schema:description "Oral decitabine-cedazuridine is a pill version of the hypomethylating chemotherapy that, since May 2026, lets older AML patients take their whole venetoclax regimen at home."@en ;
  schema:url <https://onco.cc/drugs/decitabine-cedazuridine/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Decitabine/cedazuridine> ;
  owl:sameAs <http://www.wikidata.org/entity/Q97172349> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Decitabine> ;
  onco:status "approved" ;
  onco:modality "Oral hypomethylating agent" ;
  onco:approval "US 2020: MDS and CMML", "US 2026: Newly diagnosed AML, unfit for intensive induction, with venetoclax (ASCERTAIN-V)", "EU 2023: EU brand Inaqovi" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds-higher-risk/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:drugs <https://onco.cc/drugs/venetoclax/> ;
  onco:companies <https://onco.cc/companies/taiho-oncology/> ;
  onco:trials <https://onco.cc/trials/ascertain-v/> .